155 related articles for article (PubMed ID: 9566718)
21. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
Müller V; Jensen EV; Knabbe C
Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
[TBL] [Abstract][Full Text] [Related]
22. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
24. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation.
McInerney EM; Katzenellenbogen BS
J Biol Chem; 1996 Sep; 271(39):24172-8. PubMed ID: 8798658
[TBL] [Abstract][Full Text] [Related]
25. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
26. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
Levenson AS; Jordan VC
Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
[TBL] [Abstract][Full Text] [Related]
27. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
28. Basic guide to the mechanisms of antiestrogen action.
MacGregor JI; Jordan VC
Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
[TBL] [Abstract][Full Text] [Related]
29. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
30. Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells.
Hurd C; Dinda S; Khattree N; Moudgil VK
Oncogene; 1999 Jan; 18(4):1067-72. PubMed ID: 10023683
[TBL] [Abstract][Full Text] [Related]
31. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
32. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
Castro-Rivera E; Safe S
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
[TBL] [Abstract][Full Text] [Related]
33. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
34. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Sömjen D; Waisman A; Kaye AM
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.
Koshida S; Narita T; Kato H; Yoshida S; Taga T; Ohta S; Takeuchi Y
Jpn J Cancer Res; 2002 Dec; 93(12):1351-7. PubMed ID: 12495475
[TBL] [Abstract][Full Text] [Related]
36. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens.
Hua W; Christianson T; Rougeot C; Rochefort H; Clinton GM
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):279-89. PubMed ID: 8541224
[TBL] [Abstract][Full Text] [Related]
37. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
38. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor.
Jiang SY; Jordan VC
J Natl Cancer Inst; 1992 Apr; 84(8):580-91. PubMed ID: 1556769
[TBL] [Abstract][Full Text] [Related]
39. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
40. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
